Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MC4R | P32245 | 4/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303553 | 0.99 | PTGDR2 (0.39) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4310441 | 0.96 | MAPT (0.36) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4321748 | 0.96 | MAPT (0.38) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4320702 | 0.96 | PTGDR2 (0.37) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4308713 | 0.96 | PTGDR2 (0.37) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4316778 | 0.95 | MAPT (0.38) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4307784 | 0.95 | EDNRB (0.39) | MAPTMC4RMC5RMC3RMC1R | |
| SCHEMBL4305160 | 0.95 | PTGDR2 (0.38) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4307678 | 0.94 | EDNRB (0.39) | PTGDR2MAPTMC4RMC5RMC3R | |
| SCHEMBL4323847 | 0.94 | MC4R (0.36) | PTGDR2MAPTMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | PTGDR2 482/4885MAPT 498/4885MC4R 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.